9 related studies selected as ASCO! Cancer treatment will move into the era of decision-making intelligence.

Recently, at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, 9 studies on Watson Oncology Solutions (WfO) were selected by Chinese researchers to fully interpret the latest data, results and progress of Watson Oncology Solutions in china's cancer clinical applications."At this year
's ASCO conference, the artificial intelligence clinical decision support system represented by WfO is one of the most highly watched research and applications," said Liang Jun, vice president of the International Hospital of Peking University, director of oncology and director of oncology and internal medicine at Peking University International Hospital, . Compared to previous years, this year's research covers WfO's clinical application scenarios, physician and patient satisfaction, WfO and clinical experience and consistency of guidelines, and these results provide evidence for the further improvement and clinical application of WfO. "
for the development of intelligent medical status quo, Liang Jun director further demonstrated that, "At present, the intelligent medical industry has conceptual, experimental products and more real landing projects, in order to make the industry healthy and orderly sustainable development, there must be more such as IBM Watson landing strong products, for the industry to bring more vitality." "
more than 86% of doctors are satisfied that WfO
Watson Oncology Solutions has been rapidly introduced in the field of cancer therapy in China to aid decision support, but there have been few studies on clinical applications. The report "The Application and Integration of Cognitive Technology in China: Experiences and Lessons" report, published by Baiyang Intelligent Technology, found that in the WfO cooperation project provided by Baiyang to 96 hospitals in 8 provinces, more than 86% of doctors were satisfied with the quality, understandability, basic principles and literature references of the treatment regimen, based on 52,537 cases imported by 866 doctors.
at the same time, Beijing Chaoyang Chinese and Western Medicine combined with emergency rescue center, Peking University International Hospital, Shanghai Tenth People's Hospital, also issued wfO in clinical applications have a highdegree consistency report.
in view of the outstanding problem of irregular cancer treatment, Shanghai Tenth People's Hospital explores the use of WfO to conduct cancer consultation, teaching, remote consultation and case interaction discussion with junior hospitals. Through a questionnaire survey of 56 hospitals, more than 80% of hospitals are willing to participate in WfO remote consultation to learn from standardized treatment of tumors and the latest treatment progress.
Professor Xu Qing, director of the Oncology Department of shanghai's 10th People's Hospital, said that the rational use of WfO in teaching and remote consultation can effectively help and promote standardized treatment of cancer in China. At the same time, WfO promotes academic exchanges among high-level teaching hospitals and promotes the more rational use of artificial intelligence in tumor treatment.
many hospitals expect WfO to accelerate the Chineseization of
for the application of new things, there will always be different voices. WfO also faces the challenges of different voices in China, but few studies have carefully examined the causes of inconsistencies in WfO's clinical applications.
, Peking University International Hospital conducted an in-depth study of this, in the release of "China's oncology practice and clinical decision-supported treatment severity" report, through a retrospective analysis of 11 literature published in different hospitals in eight provinces of China, these studies compare WfO treatment options with oncologists or oncology committee sthem options selected, and finally concluded that the main reasons for the inconsistency are: differences in drug accessibility, differences in treatment patterns, doctors or patient preferences.
at the same time, Peking University International Hospital conducted a more in-depth study and comparison of clinical cases, and in the report "The Impact of Decision Support Systems and Guidelines on the Impact of Treatment Consistency on Response Rate to Advanced Lung Cancer", the hospital recorded the progress of tumor treatment in nearly 100 patients receiving first-line treatment to determine the impact of the actual consistency of WfO treatment options and CSCO guidelines on objective response rates. Studies have shown that programmes that are consistent with WfO but inconsistent with CSCO 2018 guidelines have the highest objective response rate, mainly because some lung cancer treatments in CSCO guidelines are not currently included in WfO.
attached:
of the results of the study.